Scanadu Finalizes Enrollment For Its Scanadu Scout Clinical Trial


Mountain View, CA-based medical device startup Scanadu has recruited 4,000 participants for the planned clinical trial of its Scanadu Scout, a Tricoder-like device that captures multiple vital signs by placing it against the temple for 10 seconds. The study is being conducted by Scripps Translational Science Institute, where Eric Topol, MD, the director of Scripps Health, explains, “As more wireless health sensors become available to consumers, it is critical that these technologies undergo independent, scientific testing to validate their effectiveness and value.”

In 2013, Scanadu launched an Indiegogo campaign to raise equity-free funds to help them develop a manufacturing process for the Scout. The campaign offered contributors their own Scanadu Scouts at a price of $199 and a promised delivery date of March 2014. The campaign was surprisingly successful, bringing in $1.6 million dollars, pre-selling over 5,000 units during the campaign, and breaking Indiegogo’s record for the highest funded campaign at the time.

Now, after a year of design problems and shipping delays, Scanadu has a small but helpful early customer base that already owns the Scout. It was these same contributors that Scanadu has now returned to to solicit participants for its clinical trial, squeezing even more value out of an already successful initial funding campaign. Remarkably, the recruitment team at Scripps has managed to recruit 4,000 of the 5,000 users that originally backed Scanadu during its Indiegogo campaign.

Over the next six months, participants will use the Scout to measure heart rate, blood pressure, blood oxygen level, and temperature. This data will feed to the user’s Scanadu app and then to Scripps, which will track usage rates across the entire participant population. In addition to tracking overall usage rates, Scripps will work with participants to quantify the device’s ease of use, and to understand how using the device impacts other health behaviors such as medication adherence and patient-to-provider communications.

Results from the study will then be used to support Scanadu’s efforts to secure FDA approval for the Scout.

Enjoy HIStalk Connect? Sign up for update alerts, or follow us at @HIStalkConnect

↑ Back to top

Founding Sponsors

Platinum Sponsors